Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
The company posted annual revenue of $133.9 million, representing a 14% increase compared to the $117.3 million recorded in fiscal 2024.
The company achieved a net income of $5 million for the year, supported by an adjusted EBITDA of $16.3 million.
Operational efficiency remained a highlight, with Xtant generating $12.5 million in cash from operations.
As of December 31, 2025, the company reported a cash balance of $17.3 million, a figure that excludes an additional $10.5 million received subsequent to the year-end.
A defining moment in the fiscal year was the completion of a major strategic transaction with Companion Spine.
Xtant finalized the sale of its Coflex and CoFix product lines, along with its international hardware portfolio, for $21.4 million in cash.
This divestiture is intended to streamline the company's operations and allow for deeper investment in its high-growth biologics and fixation platforms.
Looking ahead to 2026, Xtant issued revenue guidance in the range of $95 million to $99 million.